The upcoming 5th edition of the World Health Organization (WHO) Classification of
Haematolymphoid Tumours is part of an effort to hierarchically catalogue human cancers arising in …

Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase
inhibitors, mandate regular updating of concepts and management. A European LeukemiaNet …

The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over
the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy. …

Purpose There is a considerable variability in the level of molecular responses achieved with
imatinib therapy in patients with chronic myeloid leukemia (CML). These differences could …

Approximately 1.5 billion people worldwide are overweight or affected by obesity, and are at
risk of developing type 2 diabetes, cardiovascular disease and related metabolic and …

The introduction of selective tyrosine-kinase inhibitors (TKIs) for the treatment of chronic
myeloid leukaemia has changed patient outcome and, consequently, management of this …

Although imatinib induces marked responses in patients with chronic myeloid leukemia (CML),
resistance is increasingly problematic, and treatment options for imatinib-resistant or -…

Background A small proportion of patients with chronic myeloproliferative diseases have
constitutive activation of the gene for platelet-derived growth factor receptor beta (PDGFRB), …

Purpose Imatinib is remarkably effective in treating newly diagnosed patients with chronic
myeloid leukemia (CML) in chronic phase (CP). To date, most of the available data come from …

Purpose We studied BCR-ABL1 transcript levels in patients with chronic myeloid leukemia
in chronic phase (CML-CP) at 3, 6, and 12 months after starting imatinib to identify molecular …